相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
Gabriela Gremel et al.
BMC CANCER (2017)
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2015)
From bowel to kidneys: the role of cubilin in physiology and disease
Erik I. Christensen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
Juana Dornbusch et al.
PLOS ONE (2013)
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
A. Poprach et al.
ANNALS OF ONCOLOGY (2012)
Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines
Sebastian Szmit et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
Sebastian Szmit et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Treatment selection in metastatic renal cell carcinoma: expert consensus
Bernard Escudier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas
Caroline Kampf et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2012)
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho et al.
KOREAN JOURNAL OF UROLOGY (2012)
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma
Petri Bono et al.
ACTA ONCOLOGICA (2011)
Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
Judith Manola et al.
CLINICAL CANCER RESEARCH (2011)
Toxicities of Targeted Therapy and Their Management in Kidney Cancer
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2011)
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
Koji Miyahara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
The Human Protein Atlas as a proteomic resource for biomarker discovery
F. Ponten et al.
JOURNAL OF INTERNAL MEDICINE (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The Notch and TGF-β Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma
Jonas Sjolund et al.
PLOS ONE (2011)
Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET
Thomas E. Hutson et al.
EUROPEAN JOURNAL OF CANCER (2010)
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Camillo Porta et al.
KIDNEY INTERNATIONAL (2010)
Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
J. L. Perez-Gracia et al.
BRITISH JOURNAL OF CANCER (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor necrosis factor α as a new target for renal cell carcinoma:: Two sequential phase II trials of infliximab at standard and high dose
Michelle L. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypertension as a predictive factor of Sunitinib activity
O. Rixe et al.
ANNALS OF ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Transforming growth factor-β1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells
M Gekle et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
Megalin and cubilin, role in proximal tubule function and during development
EI Christensen et al.
PEDIATRIC NEPHROLOGY (2002)
The roles of cubilin and megalin, two multiligand receptors, in proximal tubule function: possible implication in the progression of renal disease
PJ Verroust et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
